Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
OBJECTIVE
To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).


METHODS
Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.


METHODS
University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.


METHODS
Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.Results. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.


CONCLUSIONS
Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.
Luque
A
A
Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. amneris_luque@urmc.rochester.edu
Hulse
S
S
Wang
D
D
Shahzad
U
U
Tanzman
E
E
Antenozzi
S
S
Smith
B
B
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018890:Chemoprevention / Q000009:adverse effects* / Q000706:statistics & numerical data; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009518:New York; D016273:Occupational Exposure; D009786:Occupational Health Services; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D010349:Patient Compliance; D011635:Public Health Administration; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D013333:Student Health Services; D000068698:Tenofovir; D014495:Universities; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004338:Drug Combinations; D063065:Organophosphonates; D019259:Lamivudine; D015215:Zidovudine; D000068698:Tenofovir; D000225:Adenine